At a glance
ClinicalIndex Comparison RecordN/ACompleted· 141 enrolled
Drug / intervention
Dexamethasone intravitreal implantdrug
Likely dose
Dexamethasone intravitreal implant 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Utilization Study in Patients Receiving Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
In Brief
An observational study evaluating Dexamethasone intravitreal implant for Diabetic Macular Edema. Completed, enrolled 141 participants across 1 site.
Detailed Summary
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedMar 2019
Primary CompletionJun 2019
TodayJul 2026
First PostedMar 26, 2019
Enrollment StartJan 15, 2019
Primary CompletionJun 7, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.3 years ago
Interventions
Dexamethasone intravitreal implantdrug
Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.